NCT03847519View on ClinicalTrials.gov

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

February 22, 2022

Study Completion Date

February 22, 2022

Conditions
Lung Cancer, Non-Small CellMetastatic Squamous Cell CarcinomaMetastatic Non-Squamous Cell Carcinoma
Interventions
DRUG

ADXS-503

A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.

DRUG

Pembrolizumab

a programmed death receptor-1 (PD-1)- blocking antibody.

Trial Locations (9)

10467

Montefiore Medical Center, The Bronx

22031

Virginia Cancer Specialists, Fairfax

30322

Emory University, Atlanta

61615

Illinois CancerCare, P.C., Peoria

66205

The University of Kansas Medical Center, Westwood

90095

University of California, Los Angeles, Los Angeles

91010

City of Hope, Duarte

97213

Providence Cancer Institute, Portland

07960

Atlantic Health System, Carol G Simon Cancer Center, Morristown

Sponsors

Lead Sponsor

Advaxis, Inc.
All Listed Sponsors
lead

Advaxis, Inc.

INDUSTRY

NCT03847519 - Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter